CDK4/6 inhibitors remain the gold standard in metastatic breast cancer, but oral SERDs disappoint in trials
CDK4/6 inhibitors are still the go-to first-line treatment for HR-positive, HER2-negative metastatic breast cancer, but newer oral SERDs like giredestrant and camizestrant haven't shown a PFS advantage when added to the regimen. Oncologist Matthew Goetz highlights that managing endocrine therapy resistance remains the field's biggest challenge, with PI3K pathway inhibitors and next-gen CDK4 targeting strategies offering some hope.
Explore all the latest healthcare news and insights